TA-65 and Aging Associated Microvascular Dysfunction
180 participantsStarted 2027-01-01
Plain-language summary
The goal of this clinical trial is to test whether activation of telomerase with a dietary supplement (TA-65) improves microvascular function.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Healthy Adults 18 - 35 and 65+ years of age
* Subjects with clinical diagnosis of CAD
Exclusion criteria will include:
* 36-64 years of age without clinical diagnosis of CAD
* Self-reported habitual vigorous exercise (\>20 min, 3 times per week, 1 yr)
* Major Adverse Cardiovascular Event (MACE) in the last year (heart attack, stroke)
* Heart Failure
* Renal Impairment
* \>3 Pre-existing Cardiovascular Risk Factors (healthy groups only)
* Type 1 or type 2 diabetes
* Uncontrolled hypertension
* Current tobacco use or within last 6 months
* BMI \> 35
* Hyperlipidemia
* Hypercholesterolemia
* Use of anti-coagulant drugs
* Use of anti-platelet drugs
* Erectile dysfunction medication in the past 6 months
* Use of topical/non-topical steroids in last 6 months
* Hormone replacement therapy (Post-Menopause or Gender Reassignment)
* History of retinopathy
* Documented neuromuscular disorders
* Porphyria Cutanea Tarda (blistering of skin to sun; photosensitivity)
* Pregnancy (young female subjects)
* Allergy to lidocaine
* Current diagnosis of cancer with or without active anti-cancer treatment (pharmaceuticals) or treatment within last 12 months
* Active COVID-19 or within the past 3 months
What they're measuring
1
Nitric Oxide Mediated Endothelium-Dependent Vasodilation via Laser Doppler Flowmetry Coupled with Intradermal Microdialysis